CA2808873C - Cells expressing th1 characteristics and cytolytic properties - Google Patents
Cells expressing th1 characteristics and cytolytic properties Download PDFInfo
- Publication number
- CA2808873C CA2808873C CA2808873A CA2808873A CA2808873C CA 2808873 C CA2808873 C CA 2808873C CA 2808873 A CA2808873 A CA 2808873A CA 2808873 A CA2808873 A CA 2808873A CA 2808873 C CA2808873 C CA 2808873C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- composition
- killer
- thl
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40188110P | 2010-08-20 | 2010-08-20 | |
| US61/401,881 | 2010-08-20 | ||
| US201161495055P | 2011-06-09 | 2011-06-09 | |
| US61/495,055 | 2011-06-09 | ||
| PCT/US2011/048578 WO2012024666A2 (en) | 2010-08-20 | 2011-08-22 | Cells expressing th1 characteristics and cytolytic properties |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2808873A1 CA2808873A1 (en) | 2012-02-23 |
| CA2808873C true CA2808873C (en) | 2020-02-18 |
Family
ID=45594250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2808873A Active CA2808873C (en) | 2010-08-20 | 2011-08-22 | Cells expressing th1 characteristics and cytolytic properties |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20120045423A1 (https=) |
| EP (1) | EP2606125B1 (https=) |
| JP (2) | JP6408219B2 (https=) |
| KR (1) | KR101900807B1 (https=) |
| CN (2) | CN103068973A (https=) |
| AU (1) | AU2011291477B2 (https=) |
| BR (1) | BR112013003989B1 (https=) |
| CA (1) | CA2808873C (https=) |
| DK (1) | DK2606125T3 (https=) |
| ES (1) | ES2660577T3 (https=) |
| HU (1) | HUE036094T2 (https=) |
| IL (1) | IL224813B (https=) |
| NO (1) | NO2606125T3 (https=) |
| PH (1) | PH12013500519B1 (https=) |
| PL (1) | PL2606125T3 (https=) |
| PT (1) | PT2606125T (https=) |
| SG (2) | SG10201510524TA (https=) |
| TR (1) | TR201802334T4 (https=) |
| WO (1) | WO2012024666A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2660577T3 (es) * | 2010-08-20 | 2018-03-23 | Immunovative Therapies, Ltd. | Células que expresan características y propiedades citolíticas de Th1 |
| KR101697473B1 (ko) * | 2014-11-26 | 2017-01-18 | 주식회사 녹십자랩셀 | T 세포를 이용한 자연살해세포의 배양방법 |
| CN108064176A (zh) | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| EP3633029A4 (en) | 2017-05-26 | 2021-06-09 | Green Cross Lab Cell Corporation | METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL |
| AU2019381526B2 (en) | 2018-11-14 | 2023-02-23 | Green Cross Lab Cell Corporation | Method for culturing cord blood-derived natural killer cells using transformed T-cells |
| JP7337373B2 (ja) * | 2019-07-29 | 2023-09-04 | サイアス株式会社 | 抗原特異的ｔ細胞の製造方法 |
| US11730313B2 (en) * | 2021-02-24 | 2023-08-22 | Kirsten Wilkins | Slow cooker liner system with integrated dividers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030050392A1 (en) * | 1998-09-22 | 2003-03-13 | Brother Kogyo Kabushiki Kaisha | Water-based ink for ink jetting and ink jet recording method |
| US20030194395A1 (en) * | 2001-09-17 | 2003-10-16 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| AU2002341717A1 (en) | 2001-09-17 | 2003-04-01 | Medcell Biologics, Llc. | Cell therapy system |
| US20030134415A1 (en) | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| ES2340270T3 (es) | 2002-08-23 | 2010-06-01 | Gabriele Prof. Dr. Multhoff | Granzima b dependiente de peptidos hsp70/hsp70 como inductora de apoptosis en celulas tumorales. |
| US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| CA2555714C (en) * | 2004-02-26 | 2013-12-03 | Immunovative Therapies, Ltd. | Methods for preparing t-cells for cell therapy |
| ES2660577T3 (es) | 2010-08-20 | 2018-03-23 | Immunovative Therapies, Ltd. | Células que expresan características y propiedades citolíticas de Th1 |
-
2011
- 2011-08-22 ES ES11818884.6T patent/ES2660577T3/es active Active
- 2011-08-22 JP JP2013526060A patent/JP6408219B2/ja active Active
- 2011-08-22 HU HUE11818884A patent/HUE036094T2/hu unknown
- 2011-08-22 SG SG10201510524TA patent/SG10201510524TA/en unknown
- 2011-08-22 US US13/214,534 patent/US20120045423A1/en not_active Abandoned
- 2011-08-22 BR BR112013003989-2A patent/BR112013003989B1/pt active IP Right Grant
- 2011-08-22 CN CN2011800402324A patent/CN103068973A/zh active Pending
- 2011-08-22 PL PL11818884T patent/PL2606125T3/pl unknown
- 2011-08-22 EP EP11818884.6A patent/EP2606125B1/en active Active
- 2011-08-22 SG SG2013011069A patent/SG187846A1/en unknown
- 2011-08-22 KR KR1020137004186A patent/KR101900807B1/ko active Active
- 2011-08-22 DK DK11818884.6T patent/DK2606125T3/en active
- 2011-08-22 CN CN201810168834.1A patent/CN108245673A/zh active Pending
- 2011-08-22 AU AU2011291477A patent/AU2011291477B2/en active Active
- 2011-08-22 NO NO11818884A patent/NO2606125T3/no unknown
- 2011-08-22 PT PT118188846T patent/PT2606125T/pt unknown
- 2011-08-22 CA CA2808873A patent/CA2808873C/en active Active
- 2011-08-22 PH PH1/2013/500519A patent/PH12013500519B1/en unknown
- 2011-08-22 WO PCT/US2011/048578 patent/WO2012024666A2/en not_active Ceased
- 2011-08-22 TR TR2018/02334T patent/TR201802334T4/tr unknown
-
2013
- 2013-02-19 IL IL224813A patent/IL224813B/en active IP Right Grant
- 2013-03-13 US US13/800,066 patent/US20130196428A1/en not_active Abandoned
- 2013-03-13 US US13/800,193 patent/US10385315B2/en active Active
-
2016
- 2016-12-02 JP JP2016235386A patent/JP6525946B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11766456B2 (en) | Method for culturing natural killer cells using T cells | |
| US10806777B2 (en) | Method for allogeneic cell therapy | |
| CN102597223B (zh) | 生产天然杀伤细胞的方法 | |
| JP6525946B2 (ja) | Ｔｈ１特性と細胞溶解性を発現する細胞 | |
| KR101706524B1 (ko) | 안정성 높은 자연살해세포의 효율적인 제조방법 | |
| HK1257638A1 (en) | Cells expressing th1 characteristics and cytolytic properties | |
| HK1184498A (en) | Cells expressing th1 characteristics and cytolytic properties | |
| Baggio | Natural killer cell therapy: from bench to bedside |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160725 |